SOURCE: Basilea Pharmaceutica AG

May 05, 2008 01:16 ET

Canadian regulatory authority has accepted New Drug Submission for alitretinoin for review

BASEL, SWITZERLAND--(Marketwire - May 5, 2008) -


Basel, Switzerland, May 5, 2008 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announces that the Therapeutic Products Directorate (TPD) of Health Canada has accepted for review the New Drug Submission of oral alitretinoin for the treatment of severe refractory chronic hand eczema.

Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in several EU member states and in Switzerland.

About Basilea

Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (SWX: BSLN). The company focuses on the discovery, development and future commercialization of innovative medicines for resistant bacterial infections, systemic fungal infections, and severe skin diseases.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


For further information, please contact:

+------------------------------------------------------------------------+
|General Information                    |Investor Relations              |
|---------------------------------------+--------------------------------|
|information@basilea.com                |Dr. Barbara Zink                |
|                                       |investor_relations@basilea.com  |
+------------------------------------------------------------------------+


This press release can be downloaded from www.basilea.com

The press release can also be downloaded from the following link:

http://hugin.info/134390/R/1215397/253632.pdf



Copyright © Hugin AS 2008. All rights reserved.

Contact Information